Burkitt Lymphoma/Leukemia Study
CALGB 10002: Phase II Study of Rituximab and Short Duration, High Intensity Chemotherapy with G-CSF Support in Previously Untreated Patients with Burkitt Lymphoma/Leukemia
Protocol ID
02-101T
Protocol Description
This research is being done to understand how to improve the treatment of patients with Burkitt lymphoma/leukemia. The purpose of this study is to determine whether adding two new medications (filgrastrim, also known as G-CSF, and rituximab) to a standard treatment and eliminating radiation therapy to the brain improves overall treatment results.
Eligibility Criteria
Patients diagnosed with either Burkitt leukemia or Burkitt lymphoma
Primary Investigator(s)
- Jonathan Kolitz, MD